Outcomes of retesting BRCA negative patients using multigene panels

This study demonstrates the clinical utility of multigene panels in a group of high risk individuals who previously tested negative for aBRCA1/2 mutation. This retesting approach revealed a pathogenic mutation in 11% of cases. Retesting led to significant change in clinical management in a majority of patients with actionable mutations (7 out of 11), as well as in those with mutations in genes which do not have specific management guidelines.
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research